Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. 1995

W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D005485 Flutamide An antiandrogen with about the same potency as cyproterone in rodent and canine species. Niftolid,Apimid,Apo-Flutamide,Chimax,Cytamid,Drogenil,Euflex,Eulexin,Eulexine,Fluken,Flulem,Flumid,Fluta 1A Pharma,Fluta-GRY,Fluta-cell,Flutamin,Flutandrona,Flutaplex,Flutexin,Fugerel,Grisetin,Niftolide,Novo-Flutamide,Oncosal,PMS-Flutamide,Prostacur,Prostica,Prostogenat,SCH-13521,Testotard,Apo Flutamide,ApoFlutamide,Fluta GRY,Fluta cell,FlutaGRY,Flutacell,Novo Flutamide,NovoFlutamide,PMS Flutamide,SCH 13521,SCH13521
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
March 1993, The Journal of urology,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
July 1996, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
January 1990, European journal of cancer (Oxford, England : 1990),
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
July 1998, Hinyokika kiyo. Acta urologica Japonica,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
January 1996, International urology and nephrology,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
February 1996, The Journal of urology,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
August 1997, The Journal of urology,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
September 2017, The aging male : the official journal of the International Society for the Study of the Aging Male,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
January 1995, The Prostate,
W D Figg, and O Sartor, and M R Cooper, and A Thibault, and R C Bergan, and N Dawson, and E Reed, and C E Myers
April 1998, Cancer research,
Copied contents to your clipboard!